Table 1.

Trials of nivolumab in SCC lung.

Phase	Author	Line of treatment	Sample size	ORR (%)	PFS (months) (95% CI)	OS (months) (95% CI)	Limitations
I	Topalian NEJM2012 [Topalian et al. 2012], Gettinger JCO2015 [Gettinger et al. 2015]	Second line and beyond	54	16.7	NA	9.2 (7.3–12.5)	Small sample size Multiple treatment lines
I	Gettinger ASCO2015 [Gettinger et al. 2015]	First line	13	15	NA	18.2 (CI not reported)	Small sample size First line only
II (CHECKMATE 063)	Rizvi Lancet 2015 [Rizvi et al. 2015]	Third line and beyond	117	14.5	1.9 (1.8–3.2)	8.2 (6.1–10.9)	Heavily pretreated population, with 20.5% of patients having 4 or more lines of previous treatment
II (ONO-4538-050)	Nakagawa JTO2015 [Nakagawa et al. 2015]	Second line and beyond	35	25.7	4.2 (1.5–7.1)	Not reached (12.4–not reached)	Preliminary results Small sample size Asian population Multiple treatment lines
II (CHECKMATE 153)	Hussein WLCC2015 [Hussein et al. 2015]	Second line or more	145	13	NA	NA	Preliminary results Study compared 1 year versus continuous nivolumab Multiple treatment lines
III (CHECKMATE 017)	Brahmer NEJM2015 [Brahmer et al. 2015]	Second line	272	20	3.5 (2.1–4.9)	9.2 (7.3–13.3)	Retrospective analysis of PD-L1 expression Compared against docetaxel whereas newer regimens such as docetaxel + ramucirumab is superior to docetaxel

CI, confidence interval; NA, not available; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SCC, squamous cell carcinoma.